HDAC inhibitor M344 suppresses MCF-7 breast cancer cell proliferation

Biomedicine and Pharmacotherapy

Volumn 66, Issue 3, 2012, Pages 232-236

  Yeung, Angie ^a   Bhargava, Rishi K ^a   Ahn, Raphael ^a   Bahna, Sarra ^a   Kang, Na Hyea ^a   Lacoul, Ayush ^a   Niles, Lennard P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Apoptosis; MTT assay; P21

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 DIMETHYLAMINO N (6 HYDROXYCARBAMOYLHEXYL)BENZAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; M 344; MESSENGER RNA; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860240276     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.06.007     Document Type: Article

References (25)

1. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999, 274:34940-34947.
2. Donadelli M., Costanzo C., Faggioli L., Scupoli M.T., Moore P.S., Bassi C., et al. An inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003, 38:59-69.
3. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
4. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997, 241:142-150.
5. Huang L., Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000, 6:849-866.
6. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond. Expert Opin Investig Drugs 2007, 16:569-571.
7. Marks P.A., Richon V.M., Miller T., Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 2004, 91:137-168.
8. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61:8492-8497.
9. Fortunati N., Bertino S., Costantino L., Bosco O., Vercellinatto I., Catalano M.G., et al. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett 2008, 259:156-164.
10. Jung M., Brosch G., Kolle D., Scherf H., Gerhauser C., Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 1999, 42:4669-4679.
11. Takai N., Ueda T., Nishida M., Nasu K., Narahara H. M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. Gynecol Oncol 2006, 101:108-113.
12. Furchert S.E., Lanvers-Kaminsky C., Juurgens H., Jung M., Loidl A., Fruhwald M.C. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007, 120:1787-1794.
13. Zhang Y., Jung M., Dritschilo A., Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004, 161:667-674.
14. Laird P.W., Zijderveld A., Linders K., Rudnicki M.A., Jaenisch R., Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res 1991, 19:4293.
15. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5:981-989.
16. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734-36741.
17. Bi G., Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 2006, 3:285-290.
18. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
19. Zhuang Z.G., Fei F., Chen Y., Jin W. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin 2008, 29:1459-1466.
20. Li X., Chen B.D. Histone deacetylase inhibitor M344 inhibits cell proliferation and induces apoptosis in human THP-1 leukemia cells. Am J Biomed Sci 2009, 1:352-363.
21. Kumagai T., Wakimoto N., Yin D., Gery S., Kawamata N., Takai N., et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007, 121:656-665.
22. Xiao H., Hasegawa T., Isobe K. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 2000, 275:1371-1376.
23. Noro R., Miyanaga A., Minegishi Y., Okano T., Seike M., Soeno C., et al. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Cancer Sci 2010, 101:1424-1430.
24. Marks P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19:1049-1066.
25. Dudgeon C., Wang P., Sun X., Peng R., Sun Q., Yu J., et al. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Mol Cancer Ther 2010, 9:2893-2902.